Mycal Casey, DO, MPH,

Daratumumab is the standard of care for high risk smoldering myeloma, and should be considered as Option 1 (if available) after discussing pros and cons. It’s limited duration therapy that is approved by the FDA, and is approved in Europe. Observation alone is fraught with risk even in the best of centers. Patients find it hard to get appointments to see doctors and specialists and get the right monitoring done to prevent end organ damage. So while that option is OK for certain patients, if that option is chosen please watch closely like the control arm of AQUILA (easier said than done) and as with dara, do so after discussing pros and cons. In my experience after doing many chart reviews and reviewing lots of lots of patient records, many physicians are super confident of being able to watch closely and prevent serious end organ damage but the reality is different. nejm.org/doi/full/10.1056/NE…

#ASH24 #mmsm Few important observations on AQUILA This is in top of prior observations I shared 🧵

Excited for our 3rd year fellows all matching at their top choices for advanced fellowship! @KayShahbazian @drgemmohan @docakshatm Khalil Jalkh and Walker Barmore. #fellowshipmatch @Deya_AlkhatibMD @aroravis @MusaSharkawiMD